Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market - Nasdaq
2025-03-05 • Google News
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States.
2025-03-05 • Google News
2025-03-09 • Google News
2025-03-21 • Google News